On January 8, 2026, Just – Evotec Biologics, the Seattle–based subsidiary of Evotec SE, secured a new grant (INV072135) from the Bill & Melinda Gates Foundation. The award will underwrite ten distinct J.MD™ projects over the next three years, leveraging Evotec’s AI-driven molecular design suite to optimize monoclonal antibodies and other biologic modalities. Key development objectives include improving expression titer by up to 30%, enhancing pharmacokinetic half-life by 20–40%, reducing immunogenicity risk through in silico epitope deimmunization, and increasing thermal and formulation stability, all aimed at lowering production costs and advancing global accessibility of biotherapeutics.

The Gates Foundation’s investment underscores confidence in Evotec’s computational biodesign capabilities and accelerates the company’s push into affordable biologics for low- and middle-income countries. By targeting cost-of-goods reductions of 25% or more, the funded projects have the potential to open new markets and revenue streams for Evotec. Investors should note that successful delivery on these optimization metrics could position Evotec as a preferred contract research and manufacturing partner for global health initiatives, while strengthening its competitive edge in the growing AI-enabled drug development sector.